Join @RedChip for an investor Q&A webinar with ASP Isotopes (Nasdaq: ASPI) Executive Chairman and CEO Paul Mann, covering ASPI’s transition into commercial isotope production and its strategy at the intersection of clean energy, advanced semiconductors, and nuclear medicine.In our session, Paul addresses timelines for revenue-generating isotope shipments, updates on key facilities, capital position, and funding plans, as well as how ASPI’s partnerships could support long-term HALEU demand for next-generation nuclear reactors.ASP Isotopes is advancing proprietary isotope enrichment platforms supporting high-value end markets, including semiconductors (Silicon 28), nuclear medicine (including Yb-176 and other pipeline targets), and clean energy via HALEU supply initiatives. The company highlights definitive agreements with TerraPower for HALEU supply and financing, a joint venture with Fermi America for a U.S. enrichment presence, and a pending acquisition of Renergen to expand into helium and LNG.👉 ASP Isotopes is a client of RedChip. To learn more about ASPI and to read our full disclosure, visit: https://www.ASPIinfo.com #ASPI #Investing #SmallCapStocks #NuclearEnergy #HALEU #SMR #TerraPower #Semiconductors #Isotopes #QuantumComputing #NuclearMedicine #CleanEnergy #EnergyInvesting #TechInvesting

In our in-depth interview, Scott Monteith, CEO of Avalon Advanced Materials (OTCQB: AVLNF), breaks down why Avalon is emerging as one of North America’s most strategically positioned critical minerals companies.🔗 Avalon Advanced Materials is a client of RedChip. To learn more about AVLNF and to read our full disclosure, visit: AVLNFinfo.com.#AVLNF #LithiumStocks #RareEarthStocks #CriticalMinerals #SmallCapStocks #EVSupplyChain #CleanEnergyInvesting #StockInterviews #InvestorEducation

In this exclusive interview, Bruce Ogilvie, Executive Chairman of Alliance Entertainment (NASDAQ: AENT), outlines the company’s strategy to drive sustainable earnings growth across physical media, collectibles, and exclusive licensed content.Alliance Entertainment sits at the center of the global entertainment and collectibles ecosystem, distributing over 340,000 SKUs across vinyl, film, video games, toys, and pop culture collectibles to 35,000+ retail storefronts and 200+ e-commerce platforms. In this discussion, Ogilvie explains how Alliance’s capital-light fulfillment model, deep industry expertise, and exclusive studio relationships are creating durable competitive advantages.Key Topics Covered:• Drivers behind Alliance’s double-digit revenue growth entering fiscal 2026• Expansion of exclusive licensing agreements, including Paramount Home Entertainment• How $250M+ in trailing revenue from exclusive content builds a defensible moat• The strategic importance of Handmade by Robots, Alliance’s proprietary collectibles IP• Margin expansion driven by automation, product mix, and direct-to-consumer fulfillment• Management’s outlook for meaningful EPS growth, with earnings projected to nearly double year over yearWith physical collectibles, vinyl, and premium media formats showing renewed demand, Alliance is leveraging scale, exclusivity, and intellectual property ownership to transition toward higher-margin revenue streams while maintaining strong cash flow and balance sheet discipline.👉 Alliance Entertainment is a client of RedChip. To learn more about AENT and to read our full disclosure, visit: AENTinfo.com.#AENT #AllianceEntertainment #SmallCapStocks #InvestorInterview #StockMarketInvesting #EntertainmentStocks #MediaStocks #CollectiblesMarket #LicensingRevenue #EarningsGrowth #NASDAQStocks #ValueInvesting #GrowthStocks #WallStreet #InstitutionalInvestors #RetailInvestors #PhysicalMedia #VinylRecords #PopCultureCollectibles

In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing ~10x increase in cancer-killing metabolites while maintaining similar side effect severity versus standard capecitabine• How Processa’s approach aims to improve efficacy without increasing toxicity• Details on the formal 20-patient interim analysis evaluating safety and efficacy, expected in 2026• How this program could potentially replace current capecitabine monotherapy in certain breast cancer settings• Insights into the FDA development pathway and dose optimization ahead of a potential pivotal trial🎯 David Young brings over 40 years of experience in chemotherapy drug development, including deep expertise in 5-FU and capecitabine metabolism, which uniquely positions him to lead Processa’s clinical innovation.👉 Processa Pharmaceuticals is a client of RedChip. To learn more about PCSA and to read our full disclosure, visit: PCSAinfo.com.#ProcessaPharmaceuticals #PCSA #BiotechStocks #SmallCapStocks #Oncology #BreastCancerResearch #ClinicalTrials #Phase2Trial #CancerTherapeutics #BiotechInvesting #HealthcareStocks #NASDAQStocks #DrugDevelopment #FDAApproval #LifeSciences #GrowthStocks #InvestorInterview

In this exclusive interview, E. Will Gray II, Chairman, CEO, and Interim CFO of New Era Energy & Digital (Nasdaq: NUAI), breaks down the company’s strategy to become a critical player in AI data center infrastructure and power generation.New Era Energy & Digital is developing large scale, powered data center sites in the Permian Basin, leveraging behind the meter natural gas, future nuclear capacity, and renewable energy to meet surging demand from AI, cloud computing, and high performance computing workloads.With global spending on AI infrastructure projected to reach trillions of dollars over the next decade, NUAI is positioning itself at the intersection of energy security and digital transformation.📌 Speed to power, land availability, and cost efficiency are becoming the most critical constraints for AI data center growth. New Era Energy & Digital aims to solve these challenges with scalable, power ready sites in one of the most resource rich regions in the U.S.👉 New Era Energy & Digital is a client of RedChip. To learn more about NUAI and to read our full disclosure, visit: NUAIinfo.com.#NUAI #AIInfrastructure #DataCenters #EnergyStocks #GrowthStocks #AIInvesting #DigitalInfrastructure #InvestorInterview

In our in-depth interview, NioCorp (Nasdaq: NB) CEO Mark Smith discusses the rapidly evolving landscape for U.S. critical minerals and the company’s progress toward construction of its Elk Creek Project in Nebraska. Investors will gain insight into supply chain pressures, heavy rare earth export dynamics, and the rising strategic importance of niobium, scandium, and rare earth elements in defense and clean energy markets.🎯 Key Topics We Covered• Current global constraints impacting U.S. access to heavy rare earths• How investors should evaluate critical mineral projects using feasibility, metallurgy, permitting, and resource validation• Details on NioCorp’s collaboration with Lockheed Martin Skunk Works to advance scandium aluminum alloy technologies• Update on more than $370M raised year to date and progress with the U.S. Export Import Bank on potential project debt financing• Engineering, drilling, and site preparation milestones that position NioCorp for construction readiness📌 Why This Matters for Investors:• NioCorp is advancing one of North America’s largest critical mineral resources with all major permits secured, tier one offtake agreements in place, and growing engagement from defense and industrial end users. The company’s emphasis on feasibility-level engineering, customer-qualified metallurgy, and project financing advancement provides a clearer roadmap toward potential production.Learn more about NioCorp and the Elk Creek Project in our exclusive investor-focused conversation.NioCorp is a client of RedChip. To learn more about NB and to read our full disclosure, visit: NioCorpinfo.com.#NioCorp #NB #CriticalMinerals #RareEarths #Scandium #Niobium #DefenseIndustry #Investing #SmallCapStocks #MiningIndustry #ProjectFinancing

📌 In our exclusive interview, Nova Minerals (Nasdaq: NVA) CEO Chris Gerteisen breaks down the company’s rapid transformation into a U.S. critical minerals and gold development leader. With a $43.4 million Defense Production Act award from the U.S. Department of War, Nova is advancing toward military-grade antimony production by 2026/27 — positioning itself as the first fully integrated domestic supplier in decades.Nova’s Estelle Project in Alaska sits on a 35 km mineralized corridor hosting one of North America’s largest undeveloped gold systems, including a 5.2Moz SK-1300 pit-constrained resource. Chris discusses how the company’s latest world-class drill intercepts support strong project economics and why Nova still trades at a steep valuation discount relative to peers.👉 If you found this interview valuable, make sure to like the video, drop a comment with your thoughts or questions, and subscribe for more in-depth conversations with CEOs from emerging small-cap and microcap companies!Nova Minerals is a client of RedChip. To learn more about NVA and to read our full disclosure, visit: NVAinfo.com.#NovaMinerals #NVA #GoldStocks #CriticalMinerals #Antimony #MiningStocks #SmallCapStocks #GoldInvesting #AlaskaMining #DefenseProductionAct #USCriticalMinerals #GoldExploration

In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datasets driving new discoveries in neuropsychiatric and oncology research.• Commercial Traction: Strategic partnership with Sygnature Discovery enables global sales of BullFrog Data Networks, with up to $30M in projected revenue over 3 years.• Operational Efficiency: Lean model burning just $6M annually while advancing multiple revenue-generating programs.• Clinical Validation: Recent success in a Phase 3 oncology study with Eleison Pharmaceuticals demonstrates the power of BullFrog AI’s technology in optimizing clinical trials.• bfPREP™ Launch: New data preparation module accelerates clinical trial readiness by transforming unstructured data into AI-ready formats in days.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bullfrog AI is a client of RedChip. To learn more about BFRG and to read our full disclosure, visit: BFRGinfo.com.#BFRG #BiotechStocks #AI #DrugDiscovery #ClinicalTrials #Investing #HealthcareInnovation #SmallCapStocks #AIinBiotech